written by reader The TWO Best Speculative Stocks for 2013

By matthew7, February 27, 2013

With all the write-ups and commentary about what the top stocks are going to be for 2013… I have arrived at my own best conclusion for the TWO best stocks to own this year. I will tell you what they are and then refer you to two articles that can tell the story better than what I can here.

The first stock is Solazyme (SZYM) which I own and would be a buyer of right here at these levels. You can read an article I wrote about this stock a couple of weeks ago.

http://seekingalpha.com/article/1163621-one-stock-solazyme-for-the-coffee-can-portfolio

The other stock is Generex (GNBT) which I own and have been buying more right here at these levels. Here is an article that I read that I think really tells the value story very well.

http://seekingalpha.com/article/1145681-generex-research-for-sale-on-the-cheap

I think both of the above stocks are perfect timing for Wall Street to start recognizing the value in these stocks, starting from the middle of this year on into the end of 2013 and further into 2014. In my humble opinion both of these stocks are home runs if not grand slams!

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

8 Comments
Inline Feedbacks
View all comments
David Cannon
7 years ago

What the hell? Does Matthew Hesser represent Gumshoe or not? You publish this article,
followed by a total discalimer, and then follow that up with an invitation to join “us”
at Gumshue that to the unwary would appear to represent Mr. Hesser as representing
Gumshue. I have concluded that he is nothing more than an individual investor, and
not any kind of investment analyst. This is very misleading, and doesn’t reflect well on you.

Add a Topic
1340
Travis Johnson, Stock Gumshoe
Reply to  David Cannon

Any Irregulars can start a discussion, or make suggestions or share ideas. Anyone at all can comment on articles or postings. We want to keep things open for the exchange of ideas, but don’t want to imply that we’re reviewing or editing or vetting comments from readers. We monitor to cut down on spam and abuse, but that’s pretty much it. I don’t think one article sharing some ideas from another site constitutes abuse, though that doesn’t mean we agree with every idea or comment shared by our readers.

Reader-submitted notes like this are preceded by the little green person, list the author, and include the disclaimer you mentioned.

πŸ‘ 15731
David Cannon
7 years ago

I’m commenting again. More and more, unfortunately, this seems nothing more than
another marketing site, and gee, your apparent affiliation with Seeking Alpha is less than encouraging. Can Mr. Hesser tell any of us why we shouldn’t be convinced that gnbt isn’t headed for insolvency, i.e. bankruptcy?
David Cannon

Add a Topic
3551
tanglewood
7 years ago

Wow! talk about gambling. GNBT came on the market at 32 cents in Nov 2010 and is now selling at 3 cents. It has $18,000 in sales and $11 million in losses according to MSN Money.
http://investing.money.msn.com/investments/financial-results/?symbol=GNBT
SZYM looks like a good short right here. They lost twice as much money as they took in.
http://investing.money.msn.com/investments/financial-results/?symbol=SZYM

Add a Topic
2578
Add a Topic
899
πŸ‘ 540
Travis, not THE Travis
Travis, not THE Travis
7 years ago

David Cannon, it was perfectly clear to me that this was not endorsed by StockGumshoe.

Andrea
Andrea
7 years ago

Did Y;all skip over this little nugget at the bottom of the article? Just sayin.

“This content was written or submitted by a Stock Gumshoe Irregular, it has not been edited by Stock Gumshoe, Inc. and does not reflect the views or opinions of Stock Gumshoe or its employees. Readers who submit these comments, opinions or questions are not subject to the same trading restrictions that apply to Travis Johnson and other Stock Gumshoe employees.”

Add a Topic
5971
Add a Topic
5971
Add a Topic
5971
prmadm
7 years ago

Matthew,

Good article on Seeking Alpha regarding Solazyme. I’ve also enjoyed reading Kevin Quon’s submissions on the same subject. I’ve been an investor in Solazyme since it’s IPO. I’ve certainly taken some losses at those initial share price levels but I’ve been able to mitigate those losses by averaging down with more share purchases at lower levels than today. I’m very optimistic with this technology and the management’s ability to deliver on milestones and collaborate with industry leaders for product development/commercialization. Of course this stock is volatile (as shown historically), and will continue to be so until profitability is reached and its potential fully realized by the market. I’m happy to be able to continue to purchase shares at these levels, and believe that my patience will be rewarded exponentially over the next 2-3 years.

Aside from the shares I have in SZYM, I also dabble with option plays when I feel there’s a lucrative situation. As an example, before the recent earnings announcement I bought 10 call contracts for $.55 with a strike price of $10 for SEP 13. I suspected that there would be another collaboration announcement that might push the stock upwards near term. There was, it did, and I made a quick double in a couple of days. Playing it safe, I’ve sold half (5) of those calls today at $1.10, so that I’m now essentially playing with risk-free funds. I am expecting SZYM to reach the $12-$13 range in the near term and will sell the rest of those calls when it gets to that point.

This is a scenario I would consider repeating again–hoping for that day that an announcement is made detailing a collaboration with a major fast food company in regards to frying oils. I’m most excited about the potential fortheir nutritional tailored oils. Though, my bride is most excited about their Algenist line ($95 for a little bitty bottle–ridiculous (but people are still buying it)!).

I like covered option calls with many of the stocks in my portfolio, but not with SZYM. I really think that there will come a day when the market suddenly wakes up to this stock and it soars. I’d hate to get called out and miss that run-up. This is a buy/hold long long term story stock for me.

Anywho, this post got a little long but my intent was to let you know that I wholeheartedly agree with your assessment that Solazyme belongs in the portfolio and I’d add that 2013 could be the last year to get shares at these levels before production ramps up, future collaborations are announced, and this story catches hold in the marketplace.

Add a Topic
3551
Add a Topic
636
Add a Topic
5971
charlier1955
7 years ago

I made a little money in szym this spring when it went from 9 to 11. I strongly suspect that it will be the Apple of Biotech. It has a great research department, and an incredible line of possible products. The real question is when?

I was snooping around, trying to decide if I should buy in now since szym will announce 2nd quarter earnings next Wednesday. I am staying away, for now. There has been nothing but insider selling in the last 90 days. I am especially concerned about the option exercises and immediate sales. I am also concerned that we are due for a downdraft in the market as a whole. Szym will most likely go with it. ( I am 100% cash, but looking seriously at gold stocks and warrants) Check this out:

http://finance.yahoo.com/q/it?s=SZYM+Insider+Transactions

Add a Topic
210
Add a Topic
3229
πŸ‘ 42

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info